WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis

NCT03195634 · clinicaltrials.gov ↗

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Portal Hypertension
Cirrhosis

Interventions

DRUG: Carvedilol

Sponsor

Shanghai Changzheng Hospital

Collaborators

[object Object]